12:00 AM
 | 
Jul 20, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/17 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) UBS Jeff Elliott Price target Buy 3% $38.49
Elliot raised his target to $53 from $47 after revising his model to account for a faster than anticipated sales ramp and higher peak revenues in Japan for Soliris eculizumab. He expects the product, which is under review in Japan, will be launched there by mid-2010 to treat paroxysmal nocturnal hemoglobinuria (PNH). Elliot also lowered his FY09 EPS estimate to $0.70 from $0.71 but raised his FY10 EPS estimate to $1.34 from $1.19. The humanized mAb targeting complement C5 is already approved for the indication in the U.S., EU, Australia and Canada....

Read the full 722 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >